Ocumension Therapeutics (HKSE:01477) Total Receivables: HK$375.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01477 Ocumension Therapeutics HKSE:01477
71 GF Score
Price HK$5.06
GF Value HK$19.64
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ocumension Therapeutics Total Receivables?

Ocumension Therapeutics HKSE:01477 -1.75% 71 Total Receivables is HK$375.2 Mil as of Dec. 2025. GuruFocus rates HKSE:01477 with a GF Score™ of 71/100 and a GF Value™ of HK$19.64 (Possible Value Trap). The stock has 6 warning signs investors should review.

Ocumension Therapeutics's Total Receivables for the quarter that ended in Dec. 2025 was HK$375.2 Mil.

Ocumension Therapeutics Total Receivables Related Terms

Ocumension Therapeutics Total Receivables Historical Data

* Premium members only.

The historical data trend for Ocumension Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Total Receivables Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 54.31 125.87 130.55 175.18 375.19

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.55 162.97 175.18 189.10 375.19
HKSE:01477
71GF Score
Ocumension Therapeutics HKSE:01477
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocumension Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of HK$375.2 Mil mean?
Ocumension Therapeutics (HKSE:01477) has a Total Receivables of HK$375.2 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Ocumension Therapeutics and its competitors.
Is Ocumension Therapeutics' Total Receivables too high?
Ocumension Therapeutics' current Total Receivables is HK$375.2 Mil. Overall, Ocumension Therapeutics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Total Receivables compare to VRTX and REGN?
Ocumension Therapeutics' Total Receivables of HK$375.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Ocumension Therapeutics and its competitors. Ocumension Therapeutics's current Total Receivables is HK$375.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (HKSE:01477) is currently considered Possible Value Trap. The stock's GF Value™ is HK$19.64, compared to a current price of HK$5.06 — trading 74.2% below its estimated fair value. The current Total Receivables is HK$375.2 Mil. Ocumension Therapeutics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Ocumension Therapeutics (HKSE:01477), the current Total Receivables is HK$375.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocumension Therapeutics (HKSE:01477) Overvalued in 2026?

Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued. The current stock price of HK$5.06 is trading 74.2% below its estimated GF Value™ of HK$19.64. GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.

Key valuation signals for HKSE:01477:

  • Total Receivables: HK$375.2 Mil
  • GF Value™: HK$19.64 vs. price of HK$5.06 (74.2% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the HKSE:01477 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ocumension Therapeutics Business Description

Other Exchanges OCUTF:USA5DG:Germany
Address No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
71GF Score

Get the complete analysis for HKSE:01477

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.06
Price
HK$19.64
GF Value